Fig. 7

Efficacy of g-PPT combined with EGFR-TKIs in an H1975 tumor xenograft model (a) Flowchart of the in vivo experiments. b In vivo luciferase activity measured after the establishment of tumors in mice pretreated for four weeks with vehicle (PBS, NT), g-PPT (10 mg/kg/day), Gefitinib (50 mg/kg/day) or g-PPT (10 mg/kg/day) + Gefitinib (50 mg/kg/day). Quantification of luminescence is represented as the radiance. c-d Tumor weights and tumor growth curves for each group were obtained. p values were determined by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001. Data represent the mean ± SD of three replicate determinations. e Basal LD content of four groups of frozen subcutaneous tumor slices was assessed by Oil Red O staining (× 200/× 400 magnification). A representative image is shown from three independent experiments. f HE and IHC staining for KI67, c-Caspase3, p-EGFR and SCD1. Data represent the mean ± SD of three replicate determinations. p values were determined by one-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001. Error bars denote the SD